SAN: Sanofi - Summary | Jitta
Price
€78.81
Loss Chance
44.0%
7.00JITTA SCORE
126.35%Over Jitta Line
Jitta Ranking
118 / 541
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (60)
Recent Business Performance (84)
Financial Strength (86)
Return to Shareholders (54)
Competitive Advantage (59)
Jitta Signs
Revenue and EarningConsistent
Debt LevelLow Long Term Debt
Dividend PayoutIncreasing Every Year
CapExVery Low
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Recent Business PerformanceEarning decline 0.98% in the last year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
7.00
126.35%
4.25
207.87%
2.71
137.57%
Pharmaceuticals
3.98
100.00%
2.47
100.00%
0.01
100.00%
COMPANY DESCRIPTION
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.